From the Editors
Here's what you can expect to find in the August issue of The Oncology Pharmacist.
Patrick J. Medina, PharmD, BCOP, Steven Stricker, PharmD, MS, BCOP, Steven Stricker, PharmD, MS, BCOP
In the May issue of The Oncology Pharmacist (TOP), we feature a conversation with Patrick J. Medina, PharmD, BCOP, Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa, in which he discusses changes to the reimbursement model, bridging the knowledge gap in a rapidly evolving field, and why provider status is the “holy grail” of pharmacy.
Here's what to expect from the February issue of The Oncology Pharmacist.
In the October issue of The Oncology Pharmacist, we feature highlights from the recent Hematology/Oncology Pharmacy Association (HOPA)’s Oncology Pharmacy Practice Management Program, including an article on the challenges of managing patients with non–small-cell lung cancer (NSCLC) associated with ALK mutations. At HOPA, Jim M. Koeller, MS, Professor, College of Pharmacy, The University of Texas at Austin, discussed the current treatment guidelines for this patient population, emphasizing the need for pharmacist inclusion during testing for ALK mutations.
In this issue of The Oncology Pharmacist, we feature an article on the new—and often misunderstood—world of biosimilars
In the May issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium on the association between prophylactic gabapentin, weight loss, and narcotic dependency in patients with oropharyngeal cancer undergoing radiation therapy.
In the February issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2015 Palliative Care in Oncology Symposium on aprepitant (Emend), a centrally acting neurokinin-1 antagonist indicated for patients with chemotherapy-induced nausea and vomiting.
In the November issue of The Oncology Pharmacist, we provide a highlight of a recent study that was presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer on the use of docetaxel plus nintedanib in patients with non–small-cell lung cancer (NSCLC)
In this month’s issue of The Oncology Pharmacist, we present coverage of the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. We highlight presentations on the effectiveness of rolapitant for chemotherapy-induced nausea and vomiting, as well as data on the association between osteonecrosis of the jaw and medication.
In this month’s issue ofThe Oncology Pharmacist (TOP), we present our coverage of the news from the 11th annual Hematology/Oncology Pharmacy Association (HOPA) conference. TOP was there, and we highlight presentations about the role of pharmacists in hospice and palliative care, the disposal of oral cancer drugs, and opportunities in survivorship care.